Example 7
Approximately 10-20 mg of 1-(4-{[6-Amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone were weighed into glass vials. 7 mL of FaSSIF medium (pH 6.5, prewarmed to 37° C.) were added and the suspension was shaken at 450 rpm at 37° C. After 30 min, 60 min and 120 min, 1 mL suspension was withdrawn and filtered through a 0.2 μm syringe filter. Clear filtrate was analysed by HPLC after suitable dilution to measure the amount of API dissolved.
Results from mini dissolution studies are summarised below.
While a number of embodiments of this invention are described herein, it is apparent that the basic examples may be altered to provide other embodiments that utilize the compounds and methods of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the previously described embodiments rather than by the specific embodiments that have been represented by way of example.
